do not combine dpp-4 inhibitors with glp-1 receptor agonists recommendation Frontiers Clinical Use of DPP-4 Inhibitors

However, challenges remain

Yuan Y, Yan Z, Lao Q, Jiang N, Wu S, Lu Q, et al

The obesity segment held the largest market share in 2025

Oral medications of any kind may be affected by GLP-1 therapy because these drugs slow gastric emptying

doi: 10.2337/db18-43-OR

doi: 10.3389/fpsyt.2024.1491417 Received 04 September 2024 Accepted 29 October 2024 Published 12 November 2024 Volume 15 - 2024 Edited by Mirko Manchia, University of Cagliari, Italy Reviewed by Francesco Monaco, Azienda Sanitaria Locale Salerno, Italy Kristen Ward, University of Michigan, United States Updates Copyright 2024 Fitzgerald, Sahm, N Dhubhlaing, ODwyer, OConnell, Torrens and Crowley